Article

Long-term anticoagulant therapy for idiopathic pulmonary embolism in the elderly: a decision analysis.

Division of Pulmonary, Critical Care and Sleep Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Chest (Impact Factor: 7.13). 12/2008; 135(5):1243-51. DOI: 10.1378/chest.08-1164
Source: PubMed

ABSTRACT Elderly patients with idiopathic pulmonary embolism (PE) are at high risk for recurrent venous thromboembolic disease and might benefit from long-term anticoagulant therapy. But they are also at higher risk for bleeding complications. Because there have been no clinical trials addressing PE treatment in elderly patients, the balance of therapeutic benefits and risks is unclear.
We constructed a decision-analytic model to forecast the effects of long-term warfarin therapy for idiopathic PE. We focused on 65- and 80-year-old outpatients, with or without a propensity for falls, who previously had completed 6 to 12 months of anticoagulant therapy without experiencing a major bleed. The model incorporated age-appropriate thromboembolic recurrence rates after PE, major bleeding risks of warfarin use, and the contribution of falls to major bleeding episodes in anticoagulated elderly patients. We used probabilistic sensitivity analysis to model outcomes over ranges of potential thromboembolic and bleeding risks.
In our baseline analysis, long-term warfarin was superior to conventional duration therapy. Depending on the patient subgroup (stratified by age and fall risk), it increased life expectancy by 0.16 to 0.56 years and event-free life expectancy by 0.32 to 0.51 years. Probabilistic sensitivity analysis demonstrated that long-term warfarin therapy was likely to increase life expectancy when compared with conventional-duration therapy (76 to 93% likelihood across all groups).
Extended anticoagulant therapy for idiopathic PE may be beneficial in a subgroup of elderly patients who tolerate the initial 6 to 12 months of therapy without bleeding complications. In this population, advanced age and fall risk were not contraindications to long-term anticoagulation.

0 Bookmarks
 · 
105 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective Whether or not a high risk of falls increases the risk of bleeding in patients receiving anticoagulants remains a matter of debate.Methods We conducted a prospective cohort study involving 991 patients ≥65 years of age who received anticoagulants for acute venous thromboembolism (VTE) at 9 Swiss hospitals between September 2009 and September 2012. The study outcomes were as follows: the time to a first major episode of bleeding; and clinically-relevant non-major bleeding. We determined the associations between the risk of falls and the time to a first episode of bleeding using competing risk regression, accounting for death as a competing event. We adjusted for known bleeding risk factors and anticoagulation as a time-varying covariate.ResultsFour hundred fifty-eight of 991 patients (46%) were at high risk of falls. The mean duration of follow-up was 16.7 months. Patients at high risk of falls had a higher incidence of major bleeding (9.6 vs. 6.6 events/100 patient-years; P=0.05) and a significantly higher incidence of clinically relevant non-major bleeding (16.7 vs. 8.3 events/100 patient-years; P<0.001) than patients at low risk of falls. After adjustment, a high risk of falls was associated with clinically relevant non-major bleeding (sub-hazard ratio [SHR] = 1.74, 95% confidence interval [CI] = 1.23-2.46), but not with major bleeding (SHR = 1.24, 95% CI = 0.83-1.86).Conclusion In elderly patients who receive anticoagulants because of VTE, a high risk of falls is significantly associated with clinically-relevant non-major bleeding, but not with major bleeding. Whether or not a high risk of falls is a reason against providing anticoagulation beyond 3 months should be based on patient preferences and the risk of VTE recurrence.This article is protected by copyright. All rights reserved.
    Journal of Internal Medicine 03/2014; · 6.46 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Bij ongeveer 50% van de patiënten met een longembolie vindt men geen uitlokkende gebeurtenis. Van deze idiopathische longembolie is bekend dat de kans op een recidief twee tot drie keer groter is dan bij de longembolie waarvoor wel een verklaring kon worden gegeven, zoals een periode van immobilisatie. De gebruikelijke behandeling bestaat uit 3 tot 6 maanden orale anticoagulantia. Die behandeling is niet zonder problemen. Enerzijds kan tijdens de antistolling een bloeding optreden,wat vooral bij ouderen vaker optreedt, anderzijds kan na staken een recidief optreden. Sommigen zijn er voorstander van om wegens de kans op recidieven na het staken van de antistolling langer te ontstollen. Ofschoon tegenstanders van dit beleid vooral het verhoogde bloedingsrisico noemen, is wel gebleken dat de kans op bloedingen vooral groot is in de eerste maanden na aanvang van de antistollingstherapie.
    01/2009; 47(8):119-120.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To provide information on current evidence-based clinical management of venous thromboembolism (VTE) for nurse practitioners working for older adults in long-term care facilities. METHODS AND DATA RESOURCES: A systematic review and summary using current clinical guidelines and reliable clinical research studies: American Medical Directors Association, American College of Chest Physicians, Medline, PubMed, Refworks, and CINAHL. The management of VTE focuses on a comprehensive approach including acute and long-term pharmacologic approach, surgical and mechanical approach, prophylaxis of recurrent VTE, maintaining INR, and monitoring lab values. Recommendations based on the most current clinical research studies and guidelines will facilitate a cost-effective management of venous thromboembolism for older adults in long-term care facilities.
    Journal of the American Academy of Nurse Practitioners 06/2012; 24(6):335-44. · 0.71 Impact Factor

Alexander Goehler